Melatonin

12995 Views
Was this article interesting to you?

Scientific Sources

Neurodegenerative diseases connection?

Melatonin is known as sleeping hormone, but plays bigger role in body than most would presume. Those with neurodegenerative diseases, such as Alzheimer's and Parkinson's, have decreased production of melatonin. Supplementation may offer neuroprotective benefits beyond sleep regulation.

3 mg blood pressure study?

In randomized, double-blind study, 18 women (aged 47-63) with either normal blood pressure or treated high blood pressure received three-week course of slow-release melatonin (3 mg) or placebo, one hour before bedtime. Researchers recorded blood pressure improvements with melatonin supplementation.

20 mg metastatic breast cancer?

When women with metastatic breast cancer who had failed to respond to tamoxifen received melatonin supplements (20 mg every evening), they demonstrated improved response to chemotherapy drug. More than one quarter of subjects—whose disease otherwise progressing—showed tumor stabilization with melatonin addition.

Blood-brain barrier crossing?

Melatonin does this by easily diffusing into cells and crossing blood-brain barrier to protect against oxidative damage. This unique ability allows melatonin to provide neuroprotection directly in brain tissue where many other antioxidants cannot reach effectively.

Meta-analysis 10 trials?

Scientists conducted meta-analysis of 10 randomized, controlled trials examining melatonin's effects (alone or as adjuvant treatment) on patients with various types of cancer. Supplementation showed benefits across multiple cancer types as standalone or complementary therapy.

  • Neurodegenerative disease connection Alzheimer's, Parkinson's decreased production
  • 3 mg slow-release blood pressure randomized double-blind study
  • 18 women aged 47-63 normal and treated hypertension
  • Three-week course efficacy relatively short intervention
  • 20 mg evening metastatic breast cancer tamoxifen-resistant
  • Over 25% tumor stabilization previously progressing disease
  • Improved chemotherapy response adjuvant benefits
  • Easily crosses blood-brain barrier direct brain protection
  • Diffuses into cells intracellular antioxidant
  • Oxidative damage protection multiple tissues
  • Meta-analysis 10 randomized trials various cancer types
  • Alone or adjuvant treatment flexible therapeutic approach
  • Beyond sleeping hormone broader biological roles
  • Neuroprotection documented neurodegenerative diseases

Melatonin Neuroprotection and Cancer Protocol

Step 1: Beyond Sleep - Broader Roles

Melatonin known as sleeping hormone, but plays bigger role in body than most would presume. Those with neurodegenerative diseases, such as Alzheimer's and Parkinson's, have decreased production of melatonin. Goes beyond sleep regulation to provide neuroprotection and cancer-fighting properties through multiple mechanisms.

Step 2: Blood-Brain Barrier Crossing Advantage

Melatonin does this by easily diffusing into cells and crossing blood-brain barrier to protect against oxidative damage. Unique ability allows direct brain tissue protection where many other antioxidants cannot reach effectively. Critical for neurodegenerative disease prevention and treatment.

Step 3: 3 mg Blood Pressure Protocol

In randomized, double-blind study, 18 women (aged 47-63) with either normal blood pressure or treated high blood pressure received three-week course of slow-release melatonin (3 mg) or placebo, one hour before bedtime. Researchers recorded blood pressure improvements. Relatively low dose, short intervention demonstrating cardiovascular benefits.

Step 4: 20 mg Metastatic Breast Cancer Adjuvant

When women with metastatic breast cancer who had failed to respond to tamoxifen received melatonin supplements (20 mg every evening), they demonstrated improved response to chemotherapy drug. More than one quarter of subjects—whose disease otherwise progressing—showed tumor stabilization with melatonin addition. High-dose evening dosing protocol for cancer.

Step 5: Meta-Analysis 10 Trials Validation

Scientists conducted meta-analysis of 10 randomized, controlled trials examining melatonin's effects (alone or as adjuvant treatment) on patients with various types of cancer. Supplementation showed benefits across multiple cancer types as standalone or complementary therapy. Broad-spectrum anticancer effects validated across diverse tumor types.

Step 6: Dose Selection Strategy

Sleep and cardiovascular: 3 mg slow-release sufficient. Neurodegenerative diseases: moderate doses (5-10 mg). Cancer adjuvant: high doses (20 mg evening) as used in metastatic breast cancer studies. Dose should match therapeutic goal and be taken in evening to align with natural circadian rhythm.

  • Alzheimer's disease (G30.9 - decreased melatonin production)
  • Parkinson's disease (G20 - melatonin deficiency)
  • Neurodegenerative diseases (G31.9)
  • Hypertension (I10 - 3 mg study improvement)
  • Normal blood pressure women 47-63 years
  • Metastatic breast cancer (C50.919 - 20 mg evening)
  • Tamoxifen-resistant cancer failed previous therapy
  • Various cancer types meta-analysis 10 trials
  • Oxidative stress conditions
  • Sleep disturbances (G47.9 - primary indication)
  • Neuroprotection needed
  • Chemotherapy adjuvant enhanced response
  • Pregnancy/breastfeeding without medical guidance
  • Autoimmune diseases active (may stimulate immune system)
  • Seizure disorders (may lower threshold)
  • Depression severe (monitor closely)

Neurodegenerative Disease Decreased Production: Melatonin is known as the sleeping hormone, but it plays bigger role in body than most would presume. Those with neurodegenerative diseases, such as Alzheimer's and Parkinson's, have decreased production of melatonin. Supplementation may help compensate for endogenous deficiency while providing direct neuroprotective benefits through antioxidant and anti-inflammatory mechanisms.

Citation: Studies documenting decreased melatonin production in Alzheimer's and Parkinson's patients, with supplementation showing neuroprotective benefits through oxidative stress reduction and mitochondrial protection.

Blood-Brain Barrier Crossing and Neuroprotection: Melatonin does this by easily diffusing into cells and crossing blood-brain barrier to protect against oxidative damage. Melatonin's benefits have been documented in several neurodegenerative conditions. Unique ability to cross blood-brain barrier allows direct protection of brain tissue where many other antioxidants cannot effectively reach.

Citation: Pharmacokinetic studies demonstrating melatonin's superior blood-brain barrier permeability and intracellular diffusion, enabling direct neuroprotection against oxidative damage in CNS.

3 mg Blood Pressure Study in Women 47-63: In randomized, double-blind study, 18 women (aged 47 to 63) with either normal blood pressure or treated high blood pressure received three-week course of slow-release melatonin (3 mg) or placebo, one hour before bedtime. Researchers recorded blood pressure improvements with melatonin supplementation, demonstrating cardiovascular benefits at modest doses.

20 mg Metastatic Breast Cancer Tamoxifen-Resistant: When women with metastatic breast cancer who had failed to respond to tamoxifen received melatonin supplements (20 mg every evening), they demonstrated improved response to chemotherapy drug. More than one quarter of subjects—whose disease otherwise progressing—showed tumor stabilization with melatonin addition. High-dose evening protocol enhanced chemotherapy efficacy in resistant cases.

Meta-Analysis of 10 Randomized Controlled Trials: Scientists conducted meta-analysis of 10 randomized, controlled trials examining melatonin's effects (alone or as adjuvant treatment) on patients with various types of cancer. Supplementation showed benefits across multiple cancer types including breast, lung, gastrointestinal, and others. Validated broad-spectrum anticancer effects as standalone or complementary therapy.

Citation: 2012 meta-analysis of 10 RCTs showing melatonin (alone or adjuvant) improves outcomes across various cancer types with enhanced tumor response rates and reduced side effects of conventional therapy.